

Model Post-Exposure Prophylaxis Protocol

Anthrax Vaccine Adsorbed (BioThrax®, Cyfendus™) and Antibiotic Dispensing	
Last Reviewed	10 June 2024
Last Revised	10 June 2024
This order expires	30 June 2026

Table of contents

1. What’s new	1
2. Oregon post-exposure prophylaxis model protocol	2
3. Post-exposure schedule for anthrax	3
4. Licensed anthrax vaccine	6
5. Recommendations for use	6
6. Contraindications	6
7. Warnings and precautions	6
8. Other considerations	7
9. Side effects and adverse reactions	8
10. Storage and handling	9
11. Adverse events reporting	9
12. References	9
13. Appendix A – Preparing Doxycycline	11
14. Appendix B – Dose-sparing regimens	13

1. What’s new

Reviewed for accuracy. Added newly approved vaccine Cyfendus™. Additional minor updates and updated links.

2. Oregon post-exposure prophylaxis model protocol

- A. Check the ALERT Immunization Information System (IIS) to determine whether the patient needs this vaccine and any other vaccines.
- B. Screen clients for contraindications to fluoroquinolones, doxycycline, and anthrax vaccine, as well as risk factors noted under *Warnings and Precautions*.
- C. Provide initial 10 days of 60-day course of antimicrobial, followed by the balance of the medication at a follow-up visit 7–10 days later. In immunocompetent adults (e.g., healthy, nonpregnant adults aged 18–65 years), antimicrobial prophylaxis can be stopped 42 days after initiating vaccine if anthrax vaccine is administered on the recommended schedule. This is also true if a dose-sparing vaccine schedule is used.⁴
- D. If the medication is not available on-site, a prescription can be called or sent to the recipient's pharmacy of choice. The prescription should include the following elements: the recipient's name, full name of the authorizing prescriber, the name, strength and dosage form of the medication, the route and frequency of administration, and the amount to be dispensed.
- E. Schedule follow-up appointment to continue protocol.
- F. Provide a current Vaccine Information Statement (VIS),³ answering any questions.
- G. Record all required data elements in the client's permanent health record.
- H. Ensure epinephrine hydrochloride solution (1:1,000) and other appropriate agents and equipment are available for immediate use in case of anaphylactic or acute hypersensitivity reaction.
- I. Verify needle length for SQ or IM injection.
- J. Prepare anthrax vaccine adsorbed (AVA)
 - a. BioThrax: Shake vial thoroughly to ensure homogeneous suspension during withdrawal.¹
 - b. Cyfendus: Swirl or roll the vial to ensure homogeneous suspension. To avoid foaming, DO NOT shake.²
- K. Inspect visually for particulate matter or discoloration. If present, discard vial.
- L. Give 0.5 mL IM (Cyfendus)² or SQ (BioThrax).¹
- M. Observe client for 15 minutes after vaccination to monitor for and address any acute reaction.

Health Officer Signature

Date

Health Officer Signature

Date

3. Post-exposure schedule for anthrax⁴

Anthrax vaccine (BioThrax)			
Dose and Route: 0.5-mL, SQ*			
Unvaccinated			
Dose	Preferred age	Minimum acceptable age	Minimum acceptable spacing [†]
1	N/A	18 years [#]	
2			2 weeks dose 1 to 2
3			4 weeks dose 2 to 3
Anthrax vaccine (Cyfendus)			
Dose and Route: 0.5-mL, IM			
1	N/A	18 years [#]	
2			2 weeks dose 1 to 2
Partially vaccinated			
Complete primary series.			
Fully vaccinated			
Provide annual booster doses for persons at high-risk (BioThrax)			

*During a large-scale emergency response, initial dose of AVA can be given IM if the SQ route poses significant materiel, personnel, or clinical challenges that might delay or preclude vaccination. Persons who had adverse events from an SQ AVA dose may elect to receive subsequent doses IM after consulting with a healthcare provider.⁴

[#]Anthrax vaccine may be made available to children ≥6 weeks of age under an Investigational New Drug protocol when necessary.⁸

[†]ACIP recommends use of dose-sparing PEP regimens if the anthrax vaccine supply is insufficient to vaccinate all potentially exposed persons. A 2-full-dose strategy (0.5 mL per dose) will expand the existing vaccine supply by 50%, and the 3-half-dose strategy (0.25 mL per dose) will expand the supply by 100%. Immediately after a wide-area aerosolized release of *B. anthracis* spores, the preferred dose-sparing PEP vaccine (PEP-Vx) regimen, if needed, will be announced and authorized under an EUA. All dose-sparing PEP-Vx regimens are estimated to provide high levels of protection 2 weeks after the last dose.⁴

Recommended Initial Regimens for Antibiotic Prophylaxis (PEP-Abx)*⁸

Give one of the following for 10 days; give balance of course at follow-up visit in 7–10 days.

Population	Preferred medication choices	Dosage	Second line options	Dosage
Non-pregnant adults ≥19 years of age	Ciprofloxacin	500 mg orally twice daily	Levofloxacin [†]	750 mg orally every 24 H
	Doxycycline	100 mg orally twice daily	Moxifloxacin	400 mg orally every 24 H
	Ciprofloxacin and doxycycline are equally recommended for PEP in non-pregnant adults		Clindamycin [#]	600 mg orally every 8 H
			Consider only if susceptibility is confirmed	
			Amoxicillin	1gm every 8 H
			Penicillin VK	500 mg every 6 H
Population	Preferred medication choices	Dosage	Second line options	Dosage
Pregnant, postpartum and lactating women**	Ciprofloxacin	500 mg orally twice daily	Levofloxacin [†]	750mg orally every 24 H
			Moxifloxacin	400 mg orally every 24 H
			Clindamycin [#]	600 mg orally every 8 H
			Doxycycline**	100 mg orally twice daily
			Consider only if susceptibility confirmed	
			Amoxicillin	1gm every 8 H
			Penicillin VK	500mg every 6 H
Population	Preferred medication choices	Dosage	Second line options	Dosage

Children ≤18 years of age ^{††,‡}	Ciprofloxacin, ^{††} 15 mg/kg orally every 12 H. (not to exceed 500 mg/dose) ^{4,8} Oral suspension of ciprofloxacin is available in limited supply in the Strategic National Stockpile.	Levofloxacin [†]	<50 kg: 8 mg/kg by mouth, every 12 H (not to exceed 250 mg per dose)
	Doxycycline ^{††} (not to exceed 100 mg/dose) ⁴ ≥35 kg: 100 mg every 12 H <35 kg: 2.2 mg/kg every 12 H <14 kg: 2.2 mg/kg every 12 H (oral suspension)		>50 kg: 500 mg by mouth every 24 H
	Ciprofloxacin and doxycycline are equally recommended for PEP in non-pregnant adults		

* **N.B.:** In immunocompetent adults (e.g., healthy, nonpregnant adults aged 18–65 years), PEP-Abx given with either standard or dose-sparing PEP-Vx regimens can be stopped 42 days after initiating vaccine if AVA is administered on the recommended schedule. If the AVA series can't be completed, antimicrobial therapy should continue for 60 days.⁴ Antimicrobial should continue for 14 days after administration of the third dose of vaccine.⁴

[†]Levofloxacin is a second-line antimicrobial agent for PEP in persons aged ≥6 months with medical issues (e.g., tolerance or resistance to ciprofloxacin) that indicate its use. Safety data on extended use of levofloxacin in pediatric populations are limited beyond 14 days of therapy, and in adults are limited beyond 30 days of use; therefore, levofloxacin PEP should only be used when the benefit outweighs the risk.⁸

[#]Based on *in vitro* susceptibility data, rather than studies of clinical efficacy.⁷

^{**}The antimicrobial of choice for initial prophylaxis among pregnant women is ciprofloxacin. Doxycycline should be used with caution in asymptomatic pregnant women and only when other appropriate antimicrobial drugs are contraindicated, particularly before the third trimester. Although tetracyclines are not recommended during pregnancy, their use might be indicated for life-threatening illness.⁹

[‡]For penicillin-sensitive isolates only, use amoxicillin 25 mg/kg every 8 hours orally (maximum 500/dose); or penicillin VK 12.5-18.7 mg/kg every 6 hours orally (maximum 500 mg/dose).

^{††}Use of tetracyclines and fluoroquinolones in children can have adverse effects. These effects must be weighed carefully against the risk for developing life-threatening disease. If exposure to *B. anthracis* is confirmed, children may receive either ciprofloxacin or doxycycline as prophylaxis. However, amoxicillin is preferred for antimicrobial PEP in children when susceptibility testing indicates that the *B. anthracis* isolate is susceptible to penicillins.^{8,10}

4. Licensed anthrax vaccine

Product Name	Vaccine Components	Presentation	Acceptable Age Range
BioThrax ¹	83 kDa <i>B. anthracis</i> protective antigen protein	5 mL, 10-dose vial	18–65 years
Cyfundus ²			

5. Recommendations for use

See section 3 above.

6. Contraindications

Vaccine:

- A. Anaphylactic reaction to a previous dose of anthrax vaccine or any component of the vaccine.

Vaccine	Vaccine Excipient Summary
BioThrax ¹	1.2 mg/mL aluminum, added as aluminum hydroxide in 0.85% sodium chloride, with 25 µg/mL benzethonium chloride and 100 µg/mL formaldehyde.
Cyfundus ²	1.3 mg/mL aluminum adjuvant, 0.5 mg/mL CPG 7909 adjuvant, and 0.85% sodium chloride, with 25 µg/mL benzethonium chloride and 100 µg/mL formaldehyde.

Ciprofloxacin:

- A. Allergy to fluoroquinolones
- B. Concomitant use of Tizanidine.

Doxycycline:

- A. Allergy to tetracyclines.

7. Warnings and precautions

Vaccine:^{1,2}

- A. (BioThrax) Hypersensitivity to latex. Vial stopper contains dry, natural rubber latex.
- B. History of anthrax. Severe local reactions after vaccination in persons with a history of anthrax disease.
- C. If vaccine is administered during pregnancy, the individual should be apprised

of the potential hazard to the fetus.

- D. Persons with impaired immune response may not mount an adequate immune response.

Ciprofloxacin:⁹

- A. Use of fluoroquinolones, including ciprofloxacin, is strongly discouraged in individuals with myasthenia gravis because it may exacerbate muscle weakness.¹⁰
- B. Central nervous system or seizure disorders. ciprofloxacin may decrease seizure threshold.
- C. Co-administration of theophylline or other drugs metabolized by CYP1A2 may result in increased serum levels.
- D. Renal impairment. Altered dosage regimen indicated.

Doxycycline:¹¹

- A. Pregnancy. Evidence of human fetal risk, but use may be acceptable if benefits outweigh risks.
- B. Children under 8 years of age. Use may affect tooth development.

8. Other considerations

- A. Anthrax vaccine injections should use alternating injection sites (e.g., alternate arms) for each sequential injection.⁴
- B. Persons who experienced adverse events from AVA that was administered SQ may elect to receive subsequent vaccine doses IM after consultation with a healthcare provider.⁴
- C. During a large-scale emergency response, anthrax vaccine for post-exposure prophylaxis can be administered using an IM route if the SQ route poses significant materiel, personnel, or clinical challenges that might delay or preclude vaccination.⁴
- D. If an adult has a record of military service and does not have records available, providers can assume that the person has received all vaccines recommended by the military at the time of service entry. Serologic testing might be helpful in clarifying immune status if questions remain because at different times and

depending on military assignments, there might be inter-service and individual differences.¹⁰

- E. The serum elimination half-life of ciprofloxacin in subjects with normal renal function is approximately 4 hours. Elimination half-life is only slightly (~20%) prolonged in the elderly.⁹
- F. Continue antimicrobial PEP for 14 days after the third dose of vaccine, even if the initial vaccine administration is delayed and therefore the antimicrobial is used for >60 days.⁴
- G. In case of exposure, anthrax vaccine may be used for children 6 weeks of age and older under an Investigational New Drug protocol.⁸
- H. Duration of anthrax vaccine protection in humans after the initial priming series is unknown.¹
- I. Anthrax vaccine may be used in breastfeeding women when indicated.⁸
- J. When the *B. anthracis* strain is found to be susceptible to amoxicillin, use of amoxicillin can be considered under an investigational new drug protocol for pregnant, postpartum or lactating women, and children.⁸
- K. Anthrax vaccine may be administered to persons who have a mild illness with or without a low-grade fever.⁴

9. Side effects and adverse reactions

Adverse Events – BioThrax ¹	Frequency
Any local reaction – pain, redness, induration or swelling at injection site.	Up to 88%
Moderate to severe local reactions	Up to 4%
Any systemic reaction—fever, malaise, muscle aches, headache	Up to 75%
Tenderness in axillary lymph nodes	Up to 2%
Moderate to severe systemic reactions	Up to 5%
Adverse Events – Ciprofloxacin ⁹	
Nausea, vomiting, diarrhea, stomach pain, headache, dizziness, joint pain and rash.	
Long-term fluoroquinolone use has been associated with tendinitis and tendon tears.	
Adverse Events – Doxycycline ¹¹	
Photosensitivity of skin, nausea, vomiting, diarrhea and rash.	
Effect on tooth development in fetus if taken during last half of pregnancy or in children if taken during initial 8 years of life.	
Bismuth subsalicylate (Pepto Bismol®) may reduce absorption of tetracyclines.	

10. Storage and handling

All clinics and pharmacies enrolled with the Vaccines for Children (VFC) Program must immediately report any storage and handling deviations to the Oregon Immunization Program at 971-673-4VFC (4823).

Vaccine	Temp	Storage Issues	Notes
BioThrax ¹	Store at 2°–8°C (36°F–46°F)	Do not use if vaccine has been frozen.	The stopper of the BioThrax vial contains natural rubber latex.
Cyfeedus ²		Do not use after the expiration date on the printed label.	Cyfeedus stoppers are not made with natural rubber latex. Do not shake.

11. Adverse events reporting

Report suspected vaccine adverse events to the Vaccine Adverse Events Reporting System (VAERS) online at <https://vaers.hhs.gov/reportevent.html>. VAERS Reporting Table: <https://vaers.hhs.gov/resources/infoproviders.html>

Report suspected medication adverse events to the FDA MedWatch Program at www.fda.gov/Safety/MedWatch/default.htm

12. References

1. Emergent BioSolutions. BioThrax® (Anthrax Vaccine Adsorbed) package insert. 2015. Available at: www.fda.gov/media/71954/download. Accessed 10 June 2024.
2. Emergent BioDefense. 2023. CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) package insert. Available at: www.fda.gov/media/170445/download. Accessed 10 June 2024.
3. CDC. Vaccine Information Statement. Anthrax Vaccine. What you need to know. 2020. Available at: www.cdc.gov/vaccines/hcp/vis/vis-statements/anthrax.pdf. Accessed 10 June 2024.
4. Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR 2019; 68(RR-4):1–14. Available at: www.cdc.gov/mmwr/volumes/68/rr/rr6804a1.htm. Accessed 10 June 2024.
5. FDA. Emergency Use Authorization of Medical Products and Related Authorities: Guidance for Industry and Other Stakeholders. 2017. Available at www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm. Accessed 10

June 2024.

6. Lurie N, Frieden TR. Order permitting emergency dispensing of oral formulations of ciprofloxacin and waiver of CGMP requirements during and anthrax emergency. 2016. Available at: www.fda.gov/media/97098/download. Accessed 10 June 2024.
7. Hendricks KA, Wright ME, Shadomy SV, et. al. Center for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Technical Appendix. Diagnosis, monitoring and assessment, therapy, prophylaxis, and mortality rates of patients with anthrax. Emerg Infect Dis 2014; 20(2). Doi 10.3201/eis2002.130687. Available at: wwwnc.cdc.gov/eid/article/20/2/13-0687_article. Accessed 10 June 2024.
8. Bower WA, Yu Y, Person MK, et al. CDC guidelines for the prevention and treatment of anthrax, 2023. MMWR 2023;72(No. RR-6):1–47. Available at: www.cdc.gov/mmwr/volumes/72/rr/rr7206a1.htm. Accessed 10 June 2024.
9. Ciprofloxacin package insert: Revised March, 2020. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2020/019537s090,020780s047lbl.pdf. Accessed 10 June 2024.
10. CDC. Anthrax Emergency: How to Take Ciprofloxacin to Prevent Anthrax. EUI. August 2017. Available at: www.cdc.gov/anthrax/pdf/cipro-eui-recipients-H.pdf. Accessed 10 June 2024.
11. Drugs.com. Doxycycline Prescribing Information. Reviewed May 2024. Available at: www.drugs.com/pro/doxycycline.html. Accessed 10 June 2024.
12. Kroger A, Bahta L, Long S. Sanchez P. General Best Practice Guidelines for Immunization. Available at: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed 10 June 2024.

For more information or to clarify any part of the above protocol, consult with the vaccine recipient's primary health care provider, a consulting physician, or contact the Oregon Public Health Division's Acute and Communicable Disease Prevention section at 971-673–1111.

To request this material in an alternative format (e.g., Braille) or to clarify any part of the above order, contact the Oregon Health Authority Immunization Program at 971-673-0300 and 711 for TTY. For other questions, consult with the vaccine recipient's primary health care provider or a consulting physician.

Electronic copy of this standing protocol is available at: www.oregon.gov/standing-protocols

13. Appendix A – Preparing Doxycycline

In an Emergency: How to Prepare Doxycycline for Children and Adults Who Cannot Swallow Pills

Mixing Doxycycline Hyclate 100mg Tablets with Food

Once you have been notified by your federal, state or local authorities that you need to take doxycycline for a public health emergency, it may be necessary to prepare emergency doses of doxycycline for children and adults who cannot swallow pills.

June 2008


Prepared by the U.S. Food and Drug Administration

1

Supplies You Will Need

You will need these items to make doses of doxycycline for adults and children who cannot swallow pills:




- 1 doxycycline pill (100 mg)
(Do not take doxycycline if you are allergic to tetracyclines)
- a metal teaspoon
- 2 small bowls
- Water
- one of these foods or drinks to hide the bitter taste of crushed doxycycline:
 - milk or chocolate milk
 - chocolate pudding
 - apple juice and sugar



2

Crushing the Pill and Mixing with Water

1. Put 1 doxycycline pill in a small bowl.
2. Add 4 full teaspoons of water to the same bowl.
3. Let the pill soak in the water for 5 minutes so it will be soft.
4. Use the back of a metal teaspoon to crush the pill in the water. Crush the pill until no visible pieces remain.
5. Stir the pill and water so it is well mixed.



**You have now made the
Doxycycline and Water
Mixture.**

Child's weight:

3 Adding Food to the Doxycycline and Water Mixture to Make It Taste Better



1. Weigh your child.
2. Find your child's weight on the left side of the chart below.
3. Next, look on the right side of the chart to find the amount of the Doxycycline and Water Mixture to mix with food. The chart shows you the amount to give your child for 1 dose. (For a $\frac{1}{2}$ teaspoon dose, fill the metal teaspoon half way. It is better to give a little more of the medicine than not enough).

Child's Weight	Amount of Doxycycline and Water Mixture	Teaspoons
12 pounds or less	$\frac{1}{2}$ teaspoon	1
13 to 25 pounds	1 teaspoon	1
26 to 38 pounds	$1\frac{1}{2}$ teaspoons	1
39 to 50 pounds	2 teaspoons	1
51 to 63 pounds	$2\frac{1}{2}$ teaspoons	1
64 to 75 pounds	3 teaspoons	1
76 to 88 pounds	$3\frac{1}{2}$ teaspoons	1
89 pounds or more and adults	Use the entire mixture	Entire Mixture

4. Add the right amount of the Doxycycline and Water Mixture from the chart above to the second bowl. For adults and children 89 pounds and more, use the entire mixture.

5. Add 3 teaspoons of milk or chocolate milk or chocolate pudding or apple juice to the second bowl. If you use apple juice, also add 4 teaspoons of sugar to the second bowl.

- Stir well.



6. Go to Step 4 for dosing.

4

Dosing the Doxycycline and Water Mixture Mixed With Food



1. Give all of the Doxycycline and Water and food mixture in the second bowl. This is one dose.
2. Each child or adult should take 1 dose in the morning and 1 dose at night each day.

5

Storing the Doxycycline and Water Mixture

(If There Is Enough for Another Dose)

- If you have enough leftover doxycycline and water mixture for another dose, you can keep it for the next dose.
- The doxycycline and water mixture can be stored in a covered bowl or cup. Label and date.
- Keep the mixture in a safe place out of the reach of children.
- Store the Doxycycline and Water Mixture at room temperature for up to 24 hours.
- Throw away any unused mixture after 24 hours and make a new Doxycycline and Water Mixture before the next dose.



Do not take doxycycline if you have an allergy to tetracyclines. Get emergency help if you have any signs of an allergic reaction including hives, difficulty breathing, or swelling of your face, lips, tongue or throat.

Doxycycline may cause diarrhea, skin reaction to the sun, loss of appetite, nausea and vomiting. Birth control pills may not work as well if you take doxycycline.



Report any reaction to the medication to MedWatch at www.fda.gov/medwatch or 1-800-FDA-1088

14. Appendix B – Dose-sparing regimens

Postexposure prophylaxis with anthrax vaccine adsorbed dose-sparing regimens ³		
Dose	Route of administration	Dosing schedule
0.5 mL (full dose)	SQ or IM*	2 doses: 0 and 2-4 weeks
0.25 mL (half dose)	SQ or IM*	3 doses: 0, 2, and 4 weeks

* Can be administered IM if the SQ route of administration poses significant materiel, personnel, or clinical challenges that might delay or preclude vaccination.